SCHEMBL1627150

SCHEMBL1627150

CCc1nc2cc(C(F)(F)F)c(Cl)cc2n1-c1ccc(C[C@@H](C)N(C(=O)O)S(=O)(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGER4 P35408 1/20 0.36
MAPT P10636 2/20 0.34
P2RX3 P56373 1/20 0.34
TRPV1 Q8NER1 2/20 0.33
ALOX5 P09917 1/20 0.33
PTGS1 P23219 1/20 0.33
KEAP1 Q14145 1/20 0.33
NFE2L2 Q16236 1/20 0.33
GNRHR P30968 1/20 0.33
TRPM8 Q7Z2W7 5/20 0.33
NR1H2 P55055 1/20 0.33
NR1H3 Q13133 1/20 0.33
NPSR1 Q6W5P4 2/20 0.32
LMNA P02545 1/20 0.32
THRB P10828 1/20 0.32
HTT P42858 1/20 0.32
GPR55 Q9Y2T6 1/20 0.32
PTGER1 P34995 1/20 0.32
ALDH1A1 P00352 1/20 0.32
PKM P14618 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1624213 1.00 PTGER4 (0.36) PTGER4MAPTP2RX3TRPV1ALOX5
SCHEMBL1626123 1.00 PTGER4 (0.36) PTGER4MAPTP2RX3TRPV1ALOX5
SCHEMBL7263335 0.97 PTGER4 (0.34) PTGER4MAPTP2RX3TRPV1ALOX5
SCHEMBL1623250 0.85 PTGER4 (0.41) PTGER4MAPTGNRHRTRPM8NR1H2
SCHEMBL6713167 0.83 PTGER4 (0.41) PTGER4MAPTGNRHRTRPM8NR1H2
SCHEMBL6710720 0.82 PTGER4 (0.39) PTGER4MAPTGNRHRTRPM8NR1H2
SCHEMBL21470114 0.82 PTGER4 (0.42) PTGER4MAPTP2RX3GNRHRNR1H2
SCHEMBL30114951 0.82 PTGER4 (0.42) PTGER4MAPTP2RX3GNRHRNR1H2
SCHEMBL1625362 0.81 GAA (0.49) PTGER4MAPTP2RX3GNRHRALDH1A1
SCHEMBL1626247 0.81 GAA (0.49) PTGER4MAPTP2RX3GNRHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7928119-B2 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PFIZER INC. (US) 2011-04-19 US disclosed
US-7479564-B2 Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents RAQUALIA PHARMA INC. (JP) 2009-01-20 US disclosed
US-20070155732-A1 Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents PFIZER INC. 2007-07-05 US disclosed
US-7148234-B2 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PFIZER INC. (US) 2006-12-12 US disclosed
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases SHIMOJO MASATO 2003-12-25 US disclosed
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PFIZER PHARMACEUTICALS INC. (JP) 2002-06-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030236260-A1 Use of EP4 receptor ligands in the treatment of IL-6 involved diseases PTGER4, PTGER1, IL6 PTGER4 1/4885MAPT 4402/4885P2RX3 493/4885
US-20070155732-A1 Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents PTGS1, PTGS2, PTGES PTGER4 6/4885MAPT 3806/4885P2RX3 94/4885
US-20020077329-A1 EP4 receptor inhibitors to treat rheumatoid arthritis PTGER4, PTGER1, PTGER2 PTGER4 1/4885MAPT 4854/4885P2RX3 121/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.